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Abstract
Background:  Helical Tomotherapy (HT) integrates linear accelerator and computerized
tomography (CT) technology to deliver IMRT. Targets are localized (i.e. outlined as gross tumor
volume [GTV] and planning target volume [PTV]) on the planning kVCT study while daily MVCT is
used for correction of patient's set-up and assessment of inter-fraction anatomy changes. Based on
dosimetric comparisons, this study aims to find dosimetric equivalency between single fraction HT
and Gamma Knife® stereotactic radiosurgery (GKSRS) for the treatment of single brain metastasis.
Methods: The targeting MRI data set from the GKSRS were used for tomotherapy planning. Five
patients with single brain metastasis treated with GKSRS were re-planned in the HT planning
station using the same prescribed doses. There was no expansion of the GTV to create the PTV.
Sub-volumes were created within the PTV and prescribed to the maximum dose seen in the GKSRS
plans to imitate the hot spot normally seen in GKSRS. The PTV objective was set as a region at risk
in HT planning using the same prescribed dose to the PTV periphery as seen in the corresponding
GKSRS plan. The tumor volumes ranged from 437–1840 mm3.
Results: Conformality indices are inconsistent between HT and GKSRS. HT generally shows larger
lower isodose line volumes, has longer treatment time than GKSRS and can treat a much larger
lesion than GKSRS. Both HT and GKSRS single fraction dose-volume toxicity may be prohibitive in
treating single or multiple lesions depending on the number and the sizes of the lesions.
Conclusion: Based on the trend for larger lower dose volumes and more constricted higher dose
volumes in HT as compared to GKSRS, dosimetric equivalency was not reached between HT and
GKSRS.
Published: 03 August 2006
Radiation Oncology 2006, 1:26 doi:10.1186/1748-717X-1-26
Received: 14 April 2006
Accepted: 03 August 2006
This article is available from: http://www.ro-journal.com/content/1/1/26
© 2006 Peñagarícano et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Radiation Oncology 2006, 1:26 http://www.ro-journal.com/content/1/1/26
Page 2 of 6
(page number not for citation purposes)
Background
For patients with single brain metastasis, the addition of
surgical resection or radiosurgery to whole brain radiation
therapy improves survival [1,2]. In Gamma Knife® stereo-
tactic radiosurgery (GKSRS), a single fraction of radiation
is used to treat metastatic lesions in the brain. There
appears to be a fine line between treatment success and
the predominant form of late-toxicity from GKSRS, radia-
tion necrosis [3]. Helical tomotherapy is an emerging
technology based mainly on the linkage and integration
of known and widely-used technology in radiation oncol-
ogy into a single system, i.e. a linear accelerator and com-
puted tomography, allowing precise daily targeting of
IMRT using megavoltage CT (MVCT) guidance.
In this study we will compare dosimetric plans between
GKSRS and single fraction helical tomotherapy (HT) for
five patients with single brain metastasis by examining the
PTV coverage by the prescribed isodose surface, and the
high- and low-dose spillage volumes. As Gamma Knife® is
an accepted technology for stereotactic radiosurgery, our
goal is not show a superiority of one technology over the
other but to see if dosimetric equivalency between the two
technologies can be achieved.
Methods
Patients
Five patients with single brain metastasis were selected at
random from the pool of previously treated patients with
GKSRS. These were planned for single fraction radiosur-
gery using the Tomotherapy Hi-ART system.
Stereotactic Radiosurgery
The Gamma Knife® Model B by Elekta (Norcross, Georgia)
was used in this study. The Gamma Knife® device and the
involved radiosurgery technique have been described pre-
viously [4,5]. Briefly, patients offered GKSRS have a
Karnofsky Performance Status (KPS) equal or larger than
70 points and a single brain lesion < 3.5 cm treatment vol-
ume or volume of the prescribed isodose surface of a max-
imum of 30 cc. Patients with extracranial disease were
accepted if it was felt that their life expectancy would be at
least 6 months. On the day of the GKSRS procedure, a ster-
eotactic frame was placed under local anesthesia and a
three dimensional contrast enhanced MRI of the entire
brain was obtained. The MRI was reviewed by neuro-radi-
ology to confirm the presence of a single brain metastasis.
Then a contrast enhanced 3D SPGR (Spoiled Gradient
Recalled sequence) MRI was obtained through the area of
interest (targeting MRI) with axial images every 1 mm. The
GTV was outlined in the targeting MRI. No expansion of
the GTV was allowed to create the PTV. One or more iso-
centers were planned to create isodose lines conforming
to the three-dimensional PTV. Tumor volumes ranged
from 437 to 1840 mm3. Radiosurgery doses ranged from
16 to 20 Gy normalized to the 50% isodose line in all five
patients.
Hi-ART Tomotherapy system
In the Hi-ART Tomotherapy (Madison, Wisconsin) sys-
tem, a 6-MV linear accelerator is mounted on a ring gantry
in a CT configuration [6-8]. Opposite the linear accelera-
tor is an array of Xenon detectors capable of measuring
exit dose. The beam in a helical tomotherapy system is
collimated by a pneumatically driven multi-leaf collima-
tor that produces a fan beam with width of 0.53 to 5 cm.
Patients lay on the table that moves through the ring gan-
try while the gantry is rotating. That results in a helical
form of radiation delivery, minimizing junctional prob-
lems. The helical tomotherapy system is capable of treat-
ment delivery and acquisition of mega voltage CT (MVCT)
images with clinically satisfactory image quality and reso-
lution. By taking a CT scan before treatment, physicians
are able to verify the patient's anatomy, including tumor
characteristics and critical structures. This allows them to
quickly update any changes in the patient's position [9-
11]. The port set-up is indexed to any fixed internal struc-
tures, such as bony landmarks, rather than to external skin
markings or thermoplastic mask fiducials as is currently
done with linear accelerator-based IMRT delivery. HT has
no externally moving parts, except for the treatment table,
so there is no chance for collision.
HT planning
The targeting MRI data set and regions of interest files
were transferred to the Tomotherapy planning station via
DICOM-RT protocol. The details of the inverse planning
algorithm used in the Tomotherapy unit have been
described before [12]. The optimization is guided using
several parameters, which have been described in the lit-
erature [13]. The user defines the prescription, the jaw
opening, the modulation factor (MF), the pitch, and the
resolution of the calculation grid. Jaw opening, pitch and
MF were 0.53 centimeter, 0.200 and 2.0 for all patients,
respectively. The choice of jaw width, pitch and modula-
tion factor were chosen on the basis of obtaining a set of
optimization parameters that would allow sufficient field
overlap per gantry rotation. This in turn will allow suffi-
cient modulation of the beam within the target.
No expansion of the GTV was allowed to create the PTV.
Dose and dose-volume objectives can be defined for the
PTV and the organs at risk with differential penalties. In
order to create inhomogeneity within the PTV, sub-vol-
umes were created within the PTV. These sub-volumes
were then prescribed the maximum dose as seen in the
corresponding GKSRS plan. The PTV objective was
defined as a organ at risk in order to attempt to maintain
the periphery dose as seen in the corresponding GKSRS
plan.Radiation Oncology 2006, 1:26 http://www.ro-journal.com/content/1/1/26
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Dosimetric analysis
In each patient, dose volumes were calculated at dose lev-
els ranging from 5–40 Gy at 5 Gy volume increments. In
addition, the coverage and conformality index as
described by Paddick [14] and the total treatment time
(beam-on time) were obtained from the corresponding
planning stations for each plan.
Results
Figure 1 and figure 2 show HT and GKSRS dose distribu-
tion for one of the presented patients. Results are summa-
rized in Tables 1, 2, 3, 4, 5. In these tables patient order
reflects increasing tumor volume. For patient #1, the
higher dose volumes (15–40 Gy) were smaller for the HT
plans but the lower dose volumes (5–10 Gy) were larger
in HT plans by 1.5 and 1.06 times, respectively. The con-
formality indices (CI) and the beam-on treatment time
(T) are 0.577 & 0.597 and 43.00 & 50.77 minutes for the
HT and GKSRS plans, respectively. For patient #2, the high
dose volumes from 25–35 Gy was larger for the GKSRS
plans and the reverse was true for the low dose volume
from 5–15 Gy (range: 1.49 to 2.69 times larger). CI and T
for the HT plans as compared to GKSRS were 0.562 &
0.618 and 34.00 & 21.00 minutes, respectively. For
patient #3 with a brain stem lesion, all existing dose vol-
umes from 5–30 Gy were larger in the HT plans (1.37 to
2.89 times larger). CI and T for the HT plans as compared
to GKSRS were 0.603 & 0.593 and 30.00 & 14.16 minutes.
For patient #4, all higher dose volume from 20–30 Gy are
larger in GKSRS plan and the lower dose volumes (5–15
Gy) are comparable. CI and T for the HT plans as com-
pared to GKSRS are 0.644 & 0.696 and 36.00 & 36.70
minutes, respectively. For patient #5, all dose volumes
except 40 Gy are larger for the HT plans (1.15 to 6.49
times larger). CI and T for the HT plans as compared to
GKSRS are 0.547 & 0.507 and 49.00 & 21.00 minutes,
Represents the Tomotherapy dose distribution (in Gy) for one of the five presented patients Figure 1
Represents the Tomotherapy dose distribution (in Gy) for one of the five presented patients.
Represents the Gamma Knife dose distribution (in percent of the prescribed dose) for one of the five presented patients Figure 2
Represents the Gamma Knife dose distribution (in percent of the prescribed dose) for one of the five presented patients.Radiation Oncology 2006, 1:26 http://www.ro-journal.com/content/1/1/26
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respectively. Evaluation of the minimum dose to 100% of
the PTV volume shows that this dose is larger in all the
GKSRS plans except in patient #5 which are very similar
(15.2 Gy vs. 15.4 Gy for GKSRS and HT, respectively). It is
possible to improve this dose in the other HT plans by
manipulation of the objectives. In turn, manipulation of
the objectives in order to increase the minimum dose to
100% of the PTV's volume may result in larger lower iso-
dose volumes. Coverage of the PTV for all patients is sim-
ilar for HT and GKSR (see table 2).
Discussion
Although the PTV coverage based on CIs are comparable
between GKSRS and HT, the volume of low-dose spillage
is larger in HT than in GKSRS but comparability of tech-
niques occurs as doses converge at the prescribed dose.
Therefore, it is inadequate to perform dosimetric compar-
ison using CI or PTV coverage without evaluating the high
and low dose spillage volumes. The clinical importance of
the low-dose spillage volumes will be different in individ-
ual cases and will need clinical corroboration. The HT sin-
gle fraction dose-volume toxicity may be prohibitive in
treating single or multiple lesions depending on the
number and the sizes of the lesions due to the toxicities of
overlapping low-dose spillage volumes.
The treatment time for GKSRS depends on the prescribed
dose and the strengths of the Cobalt sources. The treat-
ment time for HT ranges from 30–49 minutes in these five
patients. The clear trend is that the treatment times are
longer in HT even when barring the possible required 1–
2 intra-fraction interruptions (HT cannot operate longer
than 30 minutes), and in two patients, much longer than
GKSRS. This interruption may not apply to all helical
tomotherapy units. Minimum dose to 100% of the PTV's
volume was also better for GKSRS in four out of the five
studied cases. Nevertheless, it is possible to improve on
this in the HT plans with a potential increase in the vol-
ume of the lower iso-doses.
The inherent property of GKSRS plan is the heterogeneous
dose distribution across the PTV. Heterogeneity within the
PTV is of benefit in terms of increasing tumor control
probability [15]. However, heterogeneity within the PTV
is detrimental when its position and extent cannot be
"planned" to coincide with tumors and happens to land
in normal tissues.
One characteristic of IMRT is the ability to create a dose
volume with very high conformality index. For the PTV,
similar conformality index can be obtained with GKSRS as
well as with HT. So the conformality index comparison is
an additional convergence point between the two tech-
niques. Both systems have very good ability to create
highly conformal volumetric dose distribution and much
will not be gained in this type of study to merely compare
conformality index. The second characteristic of IMRT is
the ability to create "simultaneous integrated boost"-type
of dose distribution. Therefore, creating a structure inside
the target as a way of planning to increase heterogeneity in
the PTV is not unreasonable as this has been normally
done in the clinic. We are demonstrating that GKSRS gives
a larger high dose volume to the target than HT. Even
when we intentionally create the hot spot in the PTV with
HT, we cannot match the kind of high dose volume
achievable with GKSRS within the PTV. In the opposite
direction as we are moving away from the prescribed isod-
ose surface, we have a smaller low dose volume in GKSRS
plan than in HT plan.
Finally, HT uses non-invasive immobilization devices and
patients are not sedated. MVCT will need to be taken peri-
odically prior to and during treatment delivery. Whereas
Table 3: Beam-on Treatment (minutes) Time of Helical 
Tomotherapy and Gamma Knife Stereotactic Radiosurgery 
Plans in Patients with Single Brain Metastasis.
TOMOTHERAPY GAMMA KNIFE
Patient #1 43.00 50.77
Patient #2 34.00 21.00
Patient #3 30.00 14.16
Patient #4 36.00 36.70
Patient #5 49.00 21.00
Table 2: Coverage of Helical Tomotherapy and Gamma Knife 
Stereotactic Radiosurgery Plans in Patients with Single Brain 
Metastasis.
TOMOTHERAPY GAMMA KNIFE
Patient #1 0.983 1.000
Patient #2 0.944 0.990
Patient #3 0.978 0.970
Patient #4 0.962 0.962
Patient #5 0.997 0.997
Coverage = (PTV volume within prescription iso-dose line)/(PTV 
volume)
Table 1: Conformality Index (CI) of Helical Tomotherapy and 
Gamma Knife Stereotactic Radiosurgery Plans in Patients with 
Single Brain Metastasis.
TOMOTHERAPY GAMMA KNIFE
Patient #1 0.577 0.597
Patient #2 0.562 0.618
Patient #3 0.603 0.593
Patient #4 0.644 0.696
Patient #5 0.547 0.507
CI = (PTV volume within the prescribed iso-dose line)2/[(tumor 
volume)*(volume of the prescribed dose)]Radiation Oncology 2006, 1:26 http://www.ro-journal.com/content/1/1/26
Page 5 of 6
(page number not for citation purposes)
the PTV coverage appears comparable to GKSRS, the HT
plans assume no patient's movement.
Conclusion
This study showed the non-dosimetric equivalency
between GKSRS and single fraction HT based on dosimet-
ric comparisons, practicality of treatment time and the
high level of confidence in PTV coverage for GKSRS over
the entire treatment duration due to the use of invasive
immobilization device. We demonstrated in our study
that the conformality achieved by both GKSRS and HT are
quite comparable. However, when we move away from
the prescribed isodose surface, we are obtaining a larger
high dose volume and a smaller low dose volume with
GKSRS in comparison with HT such that the dosimetric
and biologic advantages would be expected to be greater
with GKSRS rather than with HT. Both HT and GKSRS sin-
gle fraction dose-volume toxicity may be prohibitive in
treating single or multiple lesions depending on the
number and the sizes of the lesions. This appears to be less
of a problem for GKSRS. Finally, HT can treat a much
larger lesion than GKSRS.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
YY: Drafted the manuscript and participated in data anal-
ysis. JP: Corresponding author, prepared manuscript for
submission, created tables and results section, calculated
conformality and coverage indices, extracted data from
Gamma Knife planning system. CS: Extraction of data
from tomotherapy treatment planning systems. ML: Con-
ceived of the study and participated in data analysis. VR:
Participated in data analysis and manuscript draft.
References
1. Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger
JC, Mills M, Rogers CL, Souhami L: The American Society for
Therapeutic Radiology and Oncology (ASTRO) Evidence-
Based Review of the Role of Radiosurgery for Brain Metasta-
sis.  International Journal of Radiation Oncology Biology and Physics 2005,
63(1):37-46.
2. Tsao MN, Lloyd NS, Wong RKS, Rakovitch E, Chow E, Laperrier N:
Radiotherapeutic Management of Brain Metastasis: A Sys-
tematic Review and Meta-Analysis.  Cancer Treatment Reviews
2005, 31:256-273.
3. Korytko T, Radivoyevitch T, Colussi V, Wessels BW, Pillai K, Maciu-
nas RJ, Einstein DB: 12 Gy Gamma Knife Radiosurgical Volume
is a Predictor for Radiation Necrosis in Non-AVM Intracra-
nial Tumors.  International Journal of Radiation Oncology Biology and
Physics 2006, 64(2):419-424.
4. Lindquist C: Gamma Knife Radiosurgery.  Seminars in Radiation
Oncology 1995, 5:197-202.
5. Wu A, Lindner G, Maitz AH, Kalend AM, Lunsford LD, Flickinger JC,
Bloomer WD: Physics of Gamma Knife Approach on Conver-
gent Beams in Stereotactic Radiosurgery.  International Journal
of Radiation Oncology Biology and Physics 1990, 18:941-949.
6. Mackie TR, Balog J, Ruchala K, Shepard D, Aldridge S, Fitchard E,
Reckwerdt P, Olivera G, McNutt T, Mehta M: Tomotherapy.  Sem-
inars in Radiation Oncology 1999, 9(1):108-117.
7. Mackie TR, Holmes T, Swerdlof S: Tomotherapy: A new concept
for the delivery of dynamic conformal radiotherapy.  Medical
Physics 1993, 20(6):1709-1719.
8. Yang JN, Mackie TR, Reckwerdt P, Deasy JO, Thomadsen BR: An
investigation of tomotherapy beam delivery.  Medical Physics
1997, 24(3):425-436.
9. Kapatoes JM, Olivera GH, Reckwerdt P, Fitchard EE, Schloesser EA,
Mackie TR: Delivery verification in sequential and helical
tomotherapy.  Physics in Medicine and Biology 1999, 44:1815-1841.
10. Kapatoes JM, Olivera GH, Ruchala KJ, Smilowitz JB, Reckwerdt PJ,
Mackie TR: A feasible method for clinical delivery verification
and dose reconstruction in tomotherapy.  Medical Physics 2001,
28(4):528-542.
Table 5: Minimum dose (Gy) to 100% of the PTV volume.
TOMOTHERAPY GAMMA KNIFE
Patient #1 19.3 22.8
Patient #2 16.4 17.6
Patient #3 12.6 14.1
Patient #4 17 19.1
Patient #5 15.4 15.2
Table 4: Isodose volumes (cubic centimeter) of Helical Tomotherapy and Gamma Knife Stereotactic Radiosurgery Plans in Patients 
with Single Brain Metastasis.
Isodose 
Line
Patient #1 Patient #2 Patient #3 Patient #4 Patient #5
Tomo Vol GK Vol Tomo Vol GK Vol Tomo Vol GK Vol Tomo Vol GK Vol Tomo Vol GK Vol
40 Gy 0.009 0.009 0.001 0.001 0.000 0.000 0.000 0.000 0.000 0.000
35 Gy 0.082 0.136 0.039 0.191 0.000 0.000 0.012 0.009 0.136 0.021
30 Gy 0.208 0.332 0.159 0.320 0.028 0.016 0.096 0.138 0.756 0.119
25 Gy 0.430 0.540 0.371 0.431 0.195 0.067 0.277 0.492 1.685 0.689
20 Gy 0.748 0.905 0.709 0.589 0.476 0.225 0.584 0.938 3.093 2.418
15 Gy 1.315 1.417 1.306 0.877 0.961 0.704 1.099 1.665 5.441 4.750
10 Gy 2.851 2.678 2.865 1.545 2.111 1.344 2.363 2.997 11.986 9.339
5 Gy 11.463 7.643 11.394 4.230 8.739 3.774 9.196 8.309 47.574 22.885
Tomo Vol = Tomotherapy Volume.
GK Vol = Gamma Knife Volume.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Radiation Oncology 2006, 1:26 http://www.ro-journal.com/content/1/1/26
Page 6 of 6
(page number not for citation purposes)
11. Peñagarícano JA, Papanikolaou N: Intensity-modulated radio-
therapy for carcinoma of the head and neck.  Current Oncology
Reports 2003, 5(2):131-139.
12. Shepard DM, Olivera GH, Reckwerdt PJ, Mackie TR: Iterative
approaches to dose optimization in tomotherapy.  Physics
inMedicine and Biology 2000, 45:69-90.
13. Grigorov G, Kron T, Wong E, Chen J, Sollazzo J, Rodrigues G: Opti-
mization of helical tomotherapy treatment plans for pros-
tate cancer.  Physics in Medicine & Biology 2003, 48(13):1933-43.
14. Paddick I: A simple scoring ratio to index the conformity of
radiosurgical plans.  Journal of Neurosurgery 2000, 93(suppl
3):219-222.
15. Tome W, Fowler J: Selective boosting of tumor sub-volumes.
International Journal of Radiation Oncology Biology and Physics 2000,
48(2):593-599.